Literature DB >> 18377812

Inhaled antimicrobial therapies for respiratory infections.

Shin-Woo Kim1, Joseph L Kuti, David P Nicolau.   

Abstract

Inhaled antimicrobial therapy is attractive because of its potential to provide high concentrations of antimicrobials to the site of active respiratory infections while avoiding systemic toxicity. Many antimicrobials have been used in inhaled preparations, including aminoglycosides, colistin sodium, cephalosporins, penicillins, vancomycin, amphotericin B, and several antiviral compounds. This review highlights available data on inhaled antimicrobials, antifungals, and antivirals for the prevention and treatment of infections of the respiratory tract.

Entities:  

Year:  2008        PMID： 18377812     DOI： 10.1007/s11908-008-0007-x

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN： 1523-3847            Impact factor:   3.725


  65 in total

1.  Efficacy and feasibility of aerosolized amphotericin B lipid complex therapy in caspofungin breakthrough pulmonary zygomycosis.

Authors:  A Safdar; S O'Brien; I F Kouri
Journal:  Bone Marrow Transplant       Date:  2004-09       Impact factor: 5.483

Review 2.  Aerosolised antibiotics: a critical appraisal of their use.

Authors:  Jennifer K Hagerman; Kim E Hancock; Michael E Klepser
Journal:  Expert Opin Drug Deliv       Date:  2006-01       Impact factor: 6.648

3.  Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis.

Authors:  H Reichenspurner; P Gamberg; M Nitschke; H Valantine; S Hunt; P E Oyer; B A Reitz
Journal:  Transplant Proc       Date:  1997 Feb-Mar       Impact factor: 1.066

4.  Effect of nebulizer type and antibiotic concentration on device performance.

Authors:  A Weber; G Morlin; M Cohen; J Williams-Warren; B Ramsey; A Smith
Journal:  Pediatr Pulmonol       Date:  1997-04

5.  Tobramycin Serum Concentrations After Aerosol and Oral Administration in Cystic Fibrosis.

Authors:  Allan Weber; Judy Williams-Warren; Bonnie Ramsey; Arnold L. Smith
Journal:  Am J Ther       Date:  1995-02       Impact factor: 2.688

6.  Aerosolized pentamidine as second line therapy in patients with AIDS and Pneumocystis carinii pneumonia.

Authors:  A B Montgomery; R J Debs; J M Luce; K J Corkery; J Turner; P C Hopewell
Journal:  Chest       Date:  1989-04       Impact factor: 9.410

Review 7.  The rationale for aerosolized antibiotics.

Authors:  Patrick Flume; Michael E Klepser
Journal:  Pharmacotherapy       Date:  2002-03       Impact factor: 4.705

8.  Lung distribution and pharmacokinetics of aerosolized tobramycin.

Authors:  P Le Conte; G Potel; P Peltier; D Horeau; J Caillon; M E Juvin; M F Kerguéris; D Bugnon; D Baron
Journal:  Am Rev Respir Dis       Date:  1993-05

9.  Quantitative deposition of aerosolized gentamicin in cystic fibrosis.

Authors:  J S Ilowite; J D Gorvoy; G C Smaldone
Journal:  Am Rev Respir Dis       Date:  1987-12

10.  Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis.

Authors:  Carlos A Alvarez; Nathan P Wiederhold; Jason T McConville; Jay I Peters; Laura K Najvar; John R Graybill; Jacqueline J Coalson; Robert L Talbert; David S Burgess; Rosie Bocanegra; Keith P Johnston; Robert O Williams
Journal:  J Infect       Date:  2007-03-13       Impact factor: 6.072
View more
  2 in total

Review 1.  Inhaled drug delivery for tuberculosis therapy.

Authors:  Pavan Muttil; Chenchen Wang; Anthony J Hickey
Journal:  Pharm Res       Date:  2009-11       Impact factor: 4.200

Review 2.  Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead.

Authors:  Tony Velkov; Nusaibah Abdul Rahim; Qi Tony Zhou; Hak-Kim Chan; Jian Li
Journal:  Adv Drug Deliv Rev       Date:  2014-11-12       Impact factor: 15.470
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.